BioSpace News Archive

Zelira Therapeutics Ltd ( ASX: ZLD) (OTCQB: ZLDAF ), a global leader in the development of clinically validated cannabis medicines, is pleased to announce it has entered into a binding agreement with US-based

The Hematology/Oncology Pharmacy Association (HOPA) and Horizon CME (HCME) jointly announce their collaboration to provide BCOP accredited education to oncology pharmacists through HCME’s Advanced Practice Provider Oncology Summit (APPOS) series

Bruker Corporation (Nasdaq: BRKR) today announced the successful installation and customer acceptance of the Avance™ NEO 1.2 GHz NMR system at the Department of Chemistry and Applied Biosciences of the Eidgenössische Technische Hochschule (ETH) Zürich (www.ethz.ch) in Switzerland.

Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that it has entered into a private placement led by an undisclosed leading U.S. public investment fund specializing in life sciences as well as certain existing and new investors providing for the purchase of up to approximately $80 million of its common stock and warrants to purchase shares of Genocea commo

A new, empirical, peer-reviewed study conducted by researchers affiliated with Xavier University, Northern Kentucky University, and Seattle University has announced the results of its assessment of the psychological impact of active-shooter response training on students.

Winners to be Announced by Committee of Distinguished Scientific Leaders on October 29, 2020 at the 50th Annual Prix Galien USA Awards Ceremony in New York

Wisdom Health Genetics, the world’s leader in pet genetics and makers of the WISDOM PANEL™ dog DNA tests, announced today the publication in Genes of a study conducted by Purdue University and Wisdom Health Genetics.

Today, ATAI Life Sciences (“ATAI” or the “Company”), a global biotech developing psychedelic and non-psychedelic compounds for a variety of mental health indications, announced the launch of Viridia Life Sciences, a wholly-owned subsidiary developing novel formulations of N,N-Dimethyltryptamine (DMT) to treat a variety of mental health disorders.

Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced its preliminary unaudited revenues for its pathology services increased from $0.8M in Q1’20, to an estimated (unaudited) $1.3M in Q2’20, an increase of approximately 50% quarter-over-quarter.

Lexington Medical, a US-based medical device company delivering minimally-invasive surgical stapling solutions, and BOWA Medical, a leading innovator of energy based surgery products for medical applications, have entered into a commercial agreement the companies announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200